nejm tirzepatide New in the July 3, 2025, issue of NEJM: Exercise after Chemotherapy for Colon Cancer (CHALLENGE phase 3 trial) https://nej.md/4mh5RPL vs. Semaglutide for Obesity (SURMOUNT-5 phase 3b trial) https://nej.md/44ZeMPz Pembrolizumab in Tirzepatide for Obesity Treatment and

These distinct effects of DMF indicate a cellular context-dependent manner in ferroptosis regulation, and more additional studies are required to dissect the mechanisms in erythroblasts

Additionally, using medical and pharmacy claims data can allow health plans and PBMs to more effectively identify patients who are inappropriately prescribed diabetes-approved GLP-1 RAs in the absence of a T2DM diagnosis

This amino acid is thought to aid in weight loss by helping the body produce more energy by utilizing the bodys accumulated fat stores

Gradual titration from the lowest dose is always the safest approach when introducing a new compound with a different mechanism of action

Multiple studies have demonstrated that GLP-1RAs significantly reduce the thickness or volume of EAT: once-weekly GLP-1RAs (semaglutide, dulaglutide) significantly decrease ultrasound-measured EAT thickness in a dose-dependent manner (162)

Dietary fibre intake should be gradually increased to 30 grams per day, in line with UK recommendations